Results of a small, but unique research study, led by researchers from the Seaver Autism Center for Research and Treatment at Mount Sinai and published online in Human Genetics and Genomic Advances, suggest that low-dose ketamine is generally safe, well-tolerated and effective to treat clinical symptoms in children diagnosed with ADNP syndrome (also known as Helsmoortel-VanDerAa syndrome), a rare neurodevelopmental disorder caused by mutations in the activity dependent neuroprotective protein (ADNP) gene.
You may also be interested in:
A cap-and-invest strategy to cut transportation-related carbon emissions could provide substantial health benefits to children in New York City, with greater benefits among Black and [...]
Playgrounds are fun and can provide a great opportunity for exercise and family togetherness. But did you know that youths age 17 and younger are [...]
According to a new modeling study, published in JAMA Pediatrics, the number of children estimated to have experienced the death of a parent or caregiver [...]